Answers are grounded in this paper and cite their sources.
BACKGROUND: although rare, the incidence of anal cancer is rising in high-income countries, yet long-term national data from Spain remain limited. This study evaluated 25-year trends and cohort-specific mortality risks. METHODS: anal cancer deaths from 1999-2023 were obtained from the Spanish National Institute of Statistics. Age-standardized mortality rates (ASMRs) were calculated using the 2013 European standard population. Joinpoint regression identified temporal trends, while age-period-cohort modelling disentangled age, period, and birth cohort effects. RESULTS: among 2,549 deaths, overall ASMRs increased steadily in males (average annual percentage change [AAPC] = 2.8 %, 95 % CI: 1.8-3.8). The rates in females remained lower, ranging from 0.20 to 0.25 per 100,000, with an AAPC of 1.0 % (95 % CI: -1.1-3.2). Females showed biphasic patterns: stable rates 1999-2009 (APC = -2.2 %), then significant acceleration post-2009 (APC = 3.5 %). Mortality was concentrated in adults ≥ 50 years of age, where rates increased from 0.54 to 1.01 per 100,000 in men and 0.54 to 0.63 per 100,000 in women. Rates in those < 50 years of age remained extremely low (< 0.06 per 100,000), with declining trends in men after 2012. Age-period-cohort analysis revealed strong cohort effects, with peak mortality risk in the 1964 birth cohort (RR = 1.95 in men; RR = 1.94 in women vs 1954 cohort). Local drift analysis showed maximum annual increases at ages 55-59 years. CONCLUSIONS: anal cancer mortality in Spain has risen substantially, driven by birth cohort effects concentrated in adults ≥ 50 years of age. Elevated risks in post-1949 cohorts likely reflect increased human papillomavirus (HPV) exposure. Expanded gender-neutral HPV vaccination and targeted screening for high-risk populations are urgently needed.
No takes yet. Share an insight, caveat, or question.
Cayuela et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: